Posted by Michael Wonder on 02 Oct 2023
US FDA issues complete response letter for lebrikizumab based on inspection findings at third party manufacturer
2 October 2023 - In the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab.
Eli Lilly announced that the US FDA has issued a complete response letter for the lebrikizumab biologic license application for the treatment of moderate to severe atopic dermatitis.
